Literature DB >> 14517528

Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency.

Zubin Punthakee1, Laurent Legault, Constantin Polychronakos.   

Abstract

Prednisolone has unknown growth-suppressing effects relative to other steroids. We retrospectively studied 9 children (6 with congenital adrenal hyperplasia, CAH) receiving hydrocortisone replacement after switching to prednisolone (dose ratio, 1:5). Growth velocity and, in patients with CAH, 17-OHP decreased significantly. Dose reduction reversed these effects. Roughly, growth suppression relative potency for prednisolone:hydrocortisone was 15:1.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14517528     DOI： 10.1067/S0022-3476(03)00294-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  24 in total

1.  Assessment of bone remodelling in childhood-onset systemic lupus erythematosus.

Authors:  Julie C Baker-LePain; Mary C Nakamura; John Shepherd; Emily von Scheven
Journal:  Rheumatology (Oxford)       Date:  2010-11-23       Impact factor: 7.580

2.  Growth and development: congenital adrenal hyperplasia-glucocorticoids and height.

Authors:  Phyllis W Speiser
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

3.  The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency.

Authors:  Tony Huynh; Ivan McGown; David Cowley; Ohn Nyunt; Gary M Leong; Mark Harris; Andrew M Cotterill
Journal:  Clin Biochem Rev       Date:  2009-05

4.  Optimizing Stature in Congenital Adrenal Hyperplasia: Challenges and Solutions.

Authors:  Anju Seth
Journal:  Indian J Pediatr       Date:  2019-04-27       Impact factor: 1.967

5.  Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey.

Authors:  Christina Bothou; Gurpreet Anand; Dingfeng Li; Tina Kienitz; Khyatisha Seejore; Chiara Simeoli; Andreas Ebbehoj; Emma G Ward; Rosa Maria Paragliola; Rosario Ferrigno; Klaus Badenhoop; Sophie Bensing; Marianne Oksnes; Daniela Esposito; Ragnhildur Bergthorsdottir; William Drake; Jeanette Wahlberg; Nicole Reisch; Stefanie Hahner; Simon Pearce; Peter Trainer; Gwendolin Etzrodt-Walter; Sébastien P Thalmann; Åse B Sævik; Eystein Husebye; Andrea M Isidori; Henrik Falhammar; Gesine Meyer; Salvatore M Corsello; Rosario Pivonello; Robert Murray; Irina Bancos; Marcus Quinkler; Felix Beuschlein
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

6.  Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study.

Authors:  Emily von Scheven; Catherine M Gordon; David Wypij; Marcia Wertz; Kerry T Gallagher; Laura Bachrach
Journal:  J Pediatr Endocrinol Metab       Date:  2006-06       Impact factor: 1.634

Review 7.  Congenital adrenal hyperplasia: issues in diagnosis and treatment in children.

Authors:  Rajni Sharma; Anju Seth
Journal:  Indian J Pediatr       Date:  2013-11-20       Impact factor: 1.967

8.  Low-dose dexamethasone therapy from infancy of virilizing congenital adrenal hyperplasia.

Authors:  Scott A Rivkees; Kerry Stephenson
Journal:  Int J Pediatr Endocrinol       Date:  2010-01-14

9.  Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the "growth toxic" glucocorticoid.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-04-15

Review 10.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Felix G Riepe; Wolfgang G Sippell
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.